Clinical trial NCT02151708: Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia: Evaluation Using MRI Method
Official title: Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia:
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dyspepsia
Keywords: accommodation, emptying,motilitone
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2014-05-30
Enrollment: 78
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Functional dyspepsia (FD) is a disorder characterized by chronic or recurrent upper abdominal pain or discomfort in the absence of a specific structural cause.1 Several mechanisms have been suggested to underlie dyspeptic symptoms. In a barostat study by Tack et al.2, impaired gastric accommodation to a meal was found in 40% of patients with FD, and this abnormality was associated with early satiety. Delayed gastric emptying (GE) was also found in almost 40% of patients with FD, and was associated with the symptoms of postprandial fullness, vomiting and early satiety.3-5 Improving gastric accommodation and prokinetic effect seem to be an attractive physiological target in patients with FD. Motilitone (Dong-A ST, Yongin, Korea) is a new herbal drug that was launched in December 2011 in Korea for treating patients with FD. It has multiple mechanisms of action such as fundus relaxation, visceral analgesia and prokinetic effects.6 The current study aims to evaluate effects of motilitone on gastric emptying and accommodation after a meal in patients with FD using three-dimensional gastric volume measurements by magnetic resonance imaging (MRI). Patients are randomly allocated to receive either motilitone 90 mg daily, motilitone 180 mg daily or placebo in a double blinded manner. After 2 weeks of treatment, patients undergo gastric MRI. The primary endpoint is gastric emptying rate. The secondary endpoints are gastric accommodation and symptom improvement.

Detailed description: Same as above

Eligibility criteria: Inclusion Criteria:

1. 20 and 70 years of age
2. Diagnosed of functional dyspepsia patients by ROME III diagnostic criteria
3. Symptom scores three-point by 8 kinds of symptoms on NDI-K table
4. Signed written informed consent.

Exclusion Criteria:

1. Any functional GI diease
2. Previous abdominal surgery
3. pregnancy or lactation
4. Other conditions likely to interfere with study procedures. as judged by the investigator
5. Allergic history to motilitone
6. Contraindications to MRI
7. Significant cardiopulmonary disease
8. Significant renal(serum creatinine level≥1.5 x the upper normal limit) or liver (AST or ALT≥2.5xULN)disease
9. Can not be stopped taking medications that gastric motility booster and antacid prior to the start of the study
10. Uncontrollable diabetes mellitus (HbA1C\>7%)
11. Any malignancies within 5 years prior to the start of the study

Primary outcomes:
measure: Evaluation in gastric emptying rate after the test meal
timeFrame: Evaluation in gastric emptying rate 120min after the test meal
Secondary outcomes:
measure: The secondary endpoints are gastric accommodation and symptom improvement.
timeFrame: This outcome is measured on day 14 after 2 weeks of treatment
measure: Change in total gastric volume (TGV) after the test meal
timeFrame: This outcome is measured on day 14 after 2 weeks of treatment.The change is defined as difference between TGV 15min after the test meal and at the pre-test meal.
measure: Gastric emptying rate(GE)
timeFrame: GE 15min 30min 60min after the test meal.
measure: Change in proximal total gastric volume (TGV) after the test meal
timeFrame: The chanfe is defined as difference between proximal TGV 15min after the test meal
measure: Change in proximal to distal total gastric volume (TGV) ratio afrer the test meal
timeFrame: The change is defined as difference between proximal TGV 15min after the test meal and at the pre test meal
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Medicine, Samsung Medical Center,Sungkyunkwan University School of Medicine
Study officials:
affiliation: Samsung Medical Center
name: Poong-Lyul Rhee, MD, PhD
role: STUDY_CHAIR
References: